Delcath Systems (NASDAQ:DCTH) Releases Earnings Results, Beats Estimates By $0.26 EPS

Delcath Systems (NASDAQ:DCTH) released its earnings results on Monday. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.26, FiscalAI reports. The company had revenue of $35.10 million for the quarter, compared to the consensus estimate of $25.99 million. Delcath Systems had a net margin of 0.56% and a return on equity of 0.46%.

Delcath Systems Stock Performance

DCTH stock opened at $14.93 on Monday. The business has a 50-day simple moving average of $15.45 and a two-hundred day simple moving average of $12.44. The company has a market capitalization of $518.06 million, a P/E ratio of 1,494.49 and a beta of 0.62. Delcath Systems has a 52-week low of $8.12 and a 52-week high of $17.42.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. Weiss Ratings cut shares of Delcath Systems from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, October 28th. Wall Street Zen raised shares of Delcath Systems from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. BTIG Research upped their price objective on shares of Delcath Systems from $17.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, August 6th. HC Wainwright reiterated a “buy” rating and set a $32.00 price objective (up from $30.00) on shares of Delcath Systems in a report on Friday, August 7th. Finally, Zacks Research cut shares of Delcath Systems from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 6th. Two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $26.67.

Delcath Systems Company Profile

Delcath Systems, Inc is a medical technology company focused on liver-directed cancer treatments. The company develops and commercializes systems designed to deliver high concentrations of chemotherapy to the liver while limiting exposure to the rest of the body.

Its primary product in the United States is the HEPZATO KIT, a liver-directed therapy that combines the company’s proprietary hepatic delivery system with melphalan hydrochloride for injection. HEPZATO is approved for the treatment of adult patients with unresectable metastatic uveal melanoma involving the liver, without extrahepatic disease or with limited extrahepatic disease that is not clinically significant.

Outside the United States, Delcath markets the corresponding system under the CHEMOSAT brand.